We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DHR:NYSEDanaher Corporation Analysis

Data as of 2026-02-21 - not real-time

$210.96

Latest Price

4/10Risk

Risk Level: Medium

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Technical indicators show a short-term bearish trend and stock is trading below its 20 and 50-day moving averages.
  • Awaiting market reaction and earnings clarity following the massive $9.9 billion Masimo acquisition.

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong free cash flow generation and low leverage support the integration of the recently acquired Masimo business.
  • Analyst consensus highlights significant upside with average price targets around $260.

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Dominant market position in life sciences and diagnostics provides a wide economic moat.
  • Consistent dividend growth and resilient long-term non-GAAP core revenue expansion.

Key Metrics & Analysis

Financial Health

Revenue Growth-1.70%
Profit Margin14.70%
P/E Ratio42.1
ROE7.10%
ROA4.40%
Debt/Equity0.35
P/B Ratio2.9
Op. Cash Flow$6.4B
Free Cash Flow$5.3B
Industry P/E35.6

Technical Analysis

TrendBearish
RSI37.8
Support$203.31
Resistance$225.41
MA 20$224.94
MA 50$228.24
MA 200$208.85
MACDBearish
VolumeIncreasing
Fear & Greed Index45

Valuation

Fair Value$235.56
Target Price$261.04
Upside/Downside23.70%
GradeFair
TypeBlend
Dividend Yield0.60%

Risk Assessment

Beta0.91
Volatility18.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.